Secondary acute myeloid leukemia (sAML) accounts for 20-30% of all AML cases, and patients in this population having a dire prognosis, given many patients advanced age and limited treatment options. While recent chemotherapy-delivery technologies have demonstrated efficacy in this patient population, lack of awareness to updates in sAML classification may impede their use. Join expert AML faculty as they review the intricacies and recent updates for sAML diagnosis and classification, as well as examine the latest clinical evidence for sAML management to optimize patient outcomes.
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/online/advancing-application-latest-clinical-data-secondary-aml
- Start Date: 2024-05-10 05:00:00
- End Date: 2024-05-10 05:00:00
- Credit Details: AAPA Category 1 Credit™️: 0.5 hours
AMA PRA Category 1 Credit™️: 0.5 hours
Nursing: 0.5 hours
Pharmacy: 0.5 hours - Commercial Support: Source: Jazz Pharmaceuticals, Inc. - Amount: 33166.67 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest